Skip to content
Article Rich – Lifestyle
Author:
Kenai Therapeutics/BIOCOM
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease
July 7, 2026
Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
March 12, 2026
Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
March 4, 2026